DDInter1328 DDInter1625
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Olaratumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Olaratumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Olaratumab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Olaratumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Olaratumab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Olaratumab may lead to a major life threatening interaction when taken with Leflunomide